Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Fig. 6

Combination therapy with ASK120067 and Ack1 inhibitors showed synergistic in vivo antitumor effects in the 67R xenograft model. a Growth of 67R xenograft tumors following daily treatment with 5 mg/kg ASK120067, 25 mg/kg dasatinib or a combination of ASK120067 and dasatinib for 21 days. b The expression levels of p-Ack1 and p-AKT in 67R xenograft tumors were assessed after 21 days of treatment. c Cell apoptosis in 67R xenograft tumors was tested by the TUNEL assay after 21 days of treatment. Significance of differences was determined by Student’s t test (∗p < 0.05, ∗∗p < 0.01). d Proposed mechanism for the efficacy of the combination strategy in ASK120067-resistant NCI-H1975 cells

Back to article page